Kimberly-Clark (KVUE) Buying Kenvue Isn't A Mistake, Asserts Jim Cramer

We recently published 11 Latest Stocks Jim Cramer Talked About. Kenvue Inc. (NYSE:KVUE) is one of the stocks Jim Cramer recently discussed.

Personal healthcare products provider Kenvue Inc. (NYSE:KVUE) has been in the news for one reason or another recently. The firm faced turmoil on the stock market in September after President Trump raised concerns about Tylenol’s link to autism. Yesterday, Kenvue Inc. (NYSE:KVUE) was in the news again after Kimberly-Clark announced that it would buy the firm for $48.7 billion. Cramer pointed out the benefits of the deal:

“But I gotta tell you, I love this deal. Okay cause where Kimberly is strong, they’re not. China. Where they’re strong, Europe, Kimberly is not. Kimberly has an understanding in data which shows that Tylenol has not been hurt by any of the problems that the government’s talked about. Remember it’s also just about pregnant women. The lawsuits, that are [inaudible], talc, to Europe, because that was carved off from JNJ. They don’t the same kind of punitive laws over there. They don’t have the huge damages. So that looked bad, it was almost like a poison pill. But it’s not that bad.”

While we acknowledge the potential of KVUE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.